Mometa Ratiopharm (Mometasone Furoate)

Mometasone furoate, the active ingredient in Mometa Ratiopharm, is a glucocorticoid presented as a nasal spray for endosinusial use. It is indicated for the treatment of inflammatory nasal conditions such as allergic rhinitis and nasal polyps. GNH USA supplies Mometa Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mometa Ratiopharm (mometasone furoate) is a glucocorticoid that reduces inflammation in the nasal passages. - Allergic rhinitis: relieves nasal congestion, itching, and sneezing caused by allergens. - Nasal polyps: decreases polyp size and improves airflow through the nasal cavity. - Seasonal allergic rhinitis: controls symptoms that flare during specific pollen seasons.

Common Side Effects: - Nasal irritation or burning sensation. - Headache. - Epistaxis (nosebleeds). - Throat irritation or dryness. - Altered taste perception. - Sneezing.

Serious or Rare Side Effects: - Adrenal suppression with prolonged high‑dose use. - Cataract formation or increased intra‑ocular pressure. - Glaucoma. - Severe allergic reaction (anaphylaxis). - Opportunistic fungal infection of the nasal mucosa. - Nasal septum perforation (very rare).

Before using Mometa Ratiopharm, consider the following precautions: - Infection risk: avoid use if active nasal or sinus infection is present. - Duration of therapy: limit continuous use to the shortest period necessary to control symptoms. - Ocular monitoring: patients with glaucoma or cataract history should have regular eye examinations. - Metabolic effects: use cautiously in patients with diabetes or hypertension, monitoring blood glucose and blood pressure. - Pediatric use: only administer to children when prescribed by a qualified clinician. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Mometasone furoate may interact with other medicines that affect corticosteroid metabolism or immune function. Major Interactions (Avoid): - Systemic corticosteroids: additive immunosuppression and adrenal suppression. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase local exposure and risk of systemic effects. - Live vaccines: concurrent use can diminish vaccine efficacy. Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, phenytoin): may reduce drug effectiveness. - Antifungal agents (e.g., fluconazole): may modestly raise systemic levels. - HIV protease inhibitors: potential for increased corticosteroid exposure.